Mitomycin Medac (Mitomycin)

Mitomycin is a bioreductive alkylating agent that becomes activated inside tumour cells. Once reduced, it forms highly reactive intermediates that create covalent cross‑links between DNA strands, preventing DNA replication and transcription. This DNA damage triggers programmed cell death, preferentially affecting rapidly dividing cancer cells.

The specific dose of Mitomycin Medac is determined by the prescribing oncologist based on the cancer type, stage, patient weight, renal function and treatment protocol. Dosing regimens can vary widely, and the prescriber will tailor the amount and schedule to achieve optimal therapeutic benefit while managing toxicity.

Mitomycin is classified as contraindicated in pregnancy because it can cause fetal harm, including birth defects and miscarriage. Women of child‑bearing potential should use effective contraception during treatment and for a period after the last dose. Breastfeeding is also discouraged, as the drug can be excreted in milk and affect the infant.

To place an order, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where applicable) and any necessary import documentation.

Mitomycin differs from many conventional chemotherapeutics because it requires enzymatic activation within tumour cells to form DNA cross‑links. Compared with agents such as cisplatin, it has a distinct toxicity profile, with notable risks of pulmonary fibrosis and hemorrhagic cystitis. Choice of therapy depends on tumour type, prior treatments, and patient tolerance.

Mitomycin Medac should be stored below 25 °C, protected from moisture, light and temperature fluctuations. Keep the product in its original packaging until use. Do not freeze the solution, and handle it with appropriate protective equipment to avoid accidental exposure.

The drug is supplied as a sterile injectable solution for intravenous infusion or intravesical instillation. Intravenous dosing is performed under controlled clinical conditions, often over a set period of minutes to hours. Intravesical administration involves filling the bladder with the solution after transurethral resection, allowing contact with the bladder lining for a prescribed dwell time.

Serious adverse events include pulmonary fibrosis, severe hemorrhagic cystitis, bone‑marrow suppression leading to life‑threatening infections or bleeding, and rare occurrences of secondary malignancies. Patients should be monitored closely for respiratory symptoms, urinary bleeding, and blood count changes throughout therapy.

Mitomycin Medac is contraindicated in patients with known hypersensitivity to mitomycin or any formulation component, in pregnant or nursing women, and in individuals with severe renal impairment or uncontrolled infections. Caution is also advised for patients with pre‑existing lung disease or significant bone‑marrow dysfunction.